AXL kinase inhibitors - Pipeline Insights, 2022
This report can be delivered to the clients within 48-72 hours
DelveInsight’s, “AXL kinase inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in AXL kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
AXL kinase inhibitors: Overview
AXL (anexelekto) is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain. Other members of the TAM family are Mer and Tyro3. AXL is widely expressed in many organs, such as macrophages, endothelial cells, heart, liver and skeletal muscle, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis. The AXL receptor tyrosine kinase (RTK) is unique in that AXL gene alterations are rare, but AXL expression is upregulated on the cell surface in many cancer types, suggesting an advantage for cancer cells. GAS6/AXL signalling functions as an important pathway driving cancer cell survival, proliferation, migration and invasion, which makes AXL a potential target in cancer treatment. AXL's crucial role in both tumour biology and therapeutic resistance, makes it an attractive target for antineoplastic therapies. Therefore, targeting the AXL to inhibit its function might be a promising strategy for the treatment of various malignant tumors. Different strategies of targeting the AXL have already been considered.
'AXL kinase inhibitors - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the AXL kinase inhibitors pipeline landscape is provided which includes the disease overview and AXL kinase inhibitors treatment guidelines. The assessment part of the report embraces, in depth AXL kinase inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, AXL kinase inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the AXL kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AXL kinase inhibitors Emerging Drugs
Further product details are provided in the report……..
AXL kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different AXL kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
AXL kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses AXL kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL kinase inhibitors drugs.
AXL kinase inhibitors Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “AXL kinase inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in AXL kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
AXL kinase inhibitors: Overview
AXL (anexelekto) is a Receptor Tyrosine Kinase (RTK) belonging to the TAM family. It is a cell-surface transmembrane receptor that exerts regulated kinase activity through its cytoplasmic domain. Other members of the TAM family are Mer and Tyro3. AXL is widely expressed in many organs, such as macrophages, endothelial cells, heart, liver and skeletal muscle, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis. The AXL receptor tyrosine kinase (RTK) is unique in that AXL gene alterations are rare, but AXL expression is upregulated on the cell surface in many cancer types, suggesting an advantage for cancer cells. GAS6/AXL signalling functions as an important pathway driving cancer cell survival, proliferation, migration and invasion, which makes AXL a potential target in cancer treatment. AXL's crucial role in both tumour biology and therapeutic resistance, makes it an attractive target for antineoplastic therapies. Therefore, targeting the AXL to inhibit its function might be a promising strategy for the treatment of various malignant tumors. Different strategies of targeting the AXL have already been considered.
'AXL kinase inhibitors - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the AXL kinase inhibitors pipeline landscape is provided which includes the disease overview and AXL kinase inhibitors treatment guidelines. The assessment part of the report embraces, in depth AXL kinase inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, AXL kinase inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence AXL kinase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve AXL kinase inhibitors.
This segment of the AXL kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AXL kinase inhibitors Emerging Drugs
- Cabozantinib: Exelixis/Ipsen
- Sitravatinib: Mirati Therapeutics/BeiGene
- Batiraxcept: Aravive
- ONO-7475: Ono Pharmaceutical
Further product details are provided in the report……..
AXL kinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different AXL kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in AXL kinase inhibitors
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Subcutaneous
- Intravenous
- Intramuscular
- Molecule Type
- Peptides
- Polymer
- Small molecule
- Product Type
AXL kinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses AXL kinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL kinase inhibitors drugs.
AXL kinase inhibitors Report Insights
- AXL kinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing AXL kinase inhibitors drugs?
- How many AXL kinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of AXL kinase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the AXL kinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for AXL kinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
AXL kinase inhibitors: Overview
? Causes
? Mechanism of Action
? Signs and Symptoms
? Diagnosis
? Disease Management
Pipeline Therapeutics
? Comparative Analysis
Therapeutic Assessment
? Assessment by Product Type
? Assessment by Stage and Product Type
? Assessment by Route of Administration
? Assessment by Stage and Route of Administration
? Assessment by Molecule Type
? Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
? Comparative Analysis
Cabozantinib: Exelixis/Ipsen
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
? Comparative Analysis
ONO-7475: Ono Pharmaceutical
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
? Comparative Analysis
AB329: AnHeart Therapeutics
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
? Comparative Analysis
AXL Preclinical program: Celldex Therapeutics
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
? Comparative Analysis
AXL kinase inhibitors Key Companies
AXL kinase inhibitors Key Products
AXL kinase inhibitors- Unmet Needs
AXL kinase inhibitors- Market Drivers and Barriers
AXL kinase inhibitors- Future Perspectives and Conclusion
AXL kinase inhibitors Analyst Views
AXL kinase inhibitors Key Companies
Appendix
Executive Summary
AXL kinase inhibitors: Overview
? Causes
? Mechanism of Action
? Signs and Symptoms
? Diagnosis
? Disease Management
Pipeline Therapeutics
? Comparative Analysis
Therapeutic Assessment
? Assessment by Product Type
? Assessment by Stage and Product Type
? Assessment by Route of Administration
? Assessment by Stage and Route of Administration
? Assessment by Molecule Type
? Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
? Comparative Analysis
Cabozantinib: Exelixis/Ipsen
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
? Comparative Analysis
ONO-7475: Ono Pharmaceutical
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
? Comparative Analysis
AB329: AnHeart Therapeutics
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
? Comparative Analysis
AXL Preclinical program: Celldex Therapeutics
? Product Description
? Research and Development
? Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
? Comparative Analysis
AXL kinase inhibitors Key Companies
AXL kinase inhibitors Key Products
AXL kinase inhibitors- Unmet Needs
AXL kinase inhibitors- Market Drivers and Barriers
AXL kinase inhibitors- Future Perspectives and Conclusion
AXL kinase inhibitors Analyst Views
AXL kinase inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for AXL kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for AXL kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for AXL kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for AXL kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
